October 29, 2009
Posted by on
As part of the Gairdner Foundation’s 50th anniversary celebrations this week, there was a breakfast panel this morning with a lot of brainpower (even for MaRS). Cal Stiller lead a discussion by David Baltimore, Phillip Sharp and Corey Goodman who between them have three Gairdner awards and two Nobel prizes.
These top-notch scientists also have truly impressive corporate expertise: Board members of Amgen, Biogen and Limerick BioPharma. They turned their attention to “unclogging the pipeline.”
David Baltimore discussed reasons we’ve seen fewer approvals:
- Higher regulatory safety barrier.
- Low-hanging fruit is gone. A lot of targets are for diseases that are not fatal in the short term, which (see #1) creates a high safety barrier. Also, he says the molecular targets are harder.
Baltimore also identified potential areas of success: a subject area (immunotherapy) and a structural area (UCLA medical center’s translational research institute).
Phillip Sharp talked about the changing structure of early stage and translational funding.
- VC is re-thinking their model, but pharmas are reaching out earlier in the pipeline with incubators and academic outreach; and there is more public funding available to move products further along the pipeline.
- Trends he identifies: personalized medicine (patient-driven with $1000 genome); and a huge role for engineers and incremental improvements.
Corey Goodman starts with some stats:
- current success rate is closer to 1 in 25, not the 1 in 10 number still cited from the 1990’s
- cost of a new drug (R&D dollars divided by successful approvals) around $3 billion.
Nevertheless, Goodman sees upside due to huge unmet medical needs, deficient pipelines and vast academic output.
Will healthcare reform plans interfere with the United States’ (hidden) subsidization of global drug development through high prices?
- Baltimore points to $80 billion pharma deal that avoided price controls, but says prices are unsustainable.
- Sharp agrees that costs can’t be a bigger part of GDP, but it’s a big bucket even at current levels and there is room for efficiencies that don’t impact reimbursement.
- Goodman says importation can’t be prevented long-term based on a safety argument, so we’ll have to deal with pricing more globally [regardless of U.S. health reform efforts].
Aren’t early-stage acquisitions still (and permanently) the outliers?
- Baltimore thinks there will be a number of early-stage transformative technolgies that yeild early successes, but VC and other early funders need to be more stringent and keep an eye on the long term potential of even very early stage products.
- Sharp thinks that academia is not well-suited to disciplined discovery, and if the policy goal is to develop more products, we’ll need structural changes in academia.
The panel wrapped up on an optimistic note. Not surprising — how can you not feel good in Gairdner season? Speaking of Gairdner season, don’t forget to check out this year’s winners.
March 31, 2009
Posted by on
This year’s Gairdner International Award winners:
- Shinya Yamanaka, for making pluripotent stem cells from epidermal somatic tissue;
- Lucy Shapiro of Stanford University and Richard Losick of Harvard University for their research on how bacteria grow, divide or become dormant; and
- Kazutoshi Mori of Kyoto University and Peter Walter of the University of California for their work on protein folding.
The inaugural Global Health Award will go to Nubia Munoz, emeritus professor of the National Cancer Institute in Colombia, for work that led to developing cervical cancer vaccines; and
The Gairdner Wightman Award, given to a Canadian who has demonstrated outstanding leadership in medicine and medical science, will be given to Dr. David Sackett “for his leadership in the fields of clinical epidemiology and evidence-based medicine.”
The awards will be presented in Toronto, at the annual symposium, this year from October 28-30. Seventy-three Gairdner winners over the past 50 years have also become Nobel laureates. Thanks to a $20-million endowment for the Gairdner Foundation from the Canadian government, each recipient this year will get $100,000, compared with the $30,000 prize that each of last year’s winners took home.